Dianthus Therapeutics (DNTH) Cash from Operations (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Cash from Operations of 30555000.0 for Q3 2025, down 43.67% year-over-year from 54246029.3 in Q3 2024, and down 27.89% quarter-over-quarter from 23892000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Cash from Operations (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 30555000.0 for Q3 2025.
- In Q3 2025, Cash from Operations fell 43.67% year-over-year to 30555000.0; the TTM figure through Sep 2025 stood at 109521000.0 (down 74.98% YoY), while the FY2024 annual figure was 78180000.0, down 112.09% from the prior year.
- Cash from Operations for Q3 2025 stood at 30555000.0, down from 23892000.0 in the prior quarter.
- The five-year high for Cash from Operations was 16375000.0 in Q3 2022, with the low at 30555000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 14941000.0 (2024), against an average of 15037842.11.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 216.41% in 2022, then plunged 207.08% in 2024.
- Dianthus Therapeutics' Cash from Operations stood at 15690000.0 in 2021, then jumped by 43.59% to 8851000.0 in 2022, then slumped by 33.93% to 11854000.0 in 2023, then sank by 131.52% to 27444000.0 in 2024, then dropped by 11.34% to 30555000.0 in 2025.
- Business Quant data shows DNTH's Cash from Operations at 30555000.0 in Q3 2025, 23892000.0 in Q2 2025, and 27630000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.56 Mn |
| Sep 30, 2025 | -30.56 Mn |
| Jun 30, 2025 | -23.89 Mn |
| Jun 30, 2025 | -23.89 Mn |
| Mar 31, 2025 | -27.63 Mn |
| Mar 31, 2025 | -27.63 Mn |
| Dec 31, 2024 | -27.44 Mn |
| Dec 31, 2024 | -27.44 Mn |
| Sep 30, 2024 | -21.27 Mn |
| Sep 30, 2024 | -21.27 Mn |
| Jun 30, 2024 | -14.53 Mn |
| Jun 30, 2024 | -14.53 Mn |
| Mar 31, 2024 | -14.94 Mn |
| Mar 31, 2024 | -14.94 Mn |
| Dec 31, 2023 | -11.85 Mn |
| Dec 31, 2023 | -11.85 Mn |
| Sep 30, 2023 | -9.99 Mn |
| Sep 30, 2023 | -9.99 Mn |
| Jun 30, 2023 | -4.73 Mn |
| Jun 30, 2023 | -4.73 Mn |